U.S. drug policy needs a dose of neuroscience

Stanford Report·Jun 22

✦ NabkaNews BriefAuto-summarized from multiple outlets · verify with the source

Research on neuroscience and its applications is being explored in relation to us drug policy. Studies have found that certain substances, such as psilocybin, can have rapid and lasting effects on conditions like chronic pain, depression, and dementia. The potential of neuroscience to inform and improve drug policy is being discussed, with various outlets reporting on developments in the field.

Full coverage

FDA Reverses Course on Neuro Drugs; Omega-3s and Dementia; Brain Death Test Lawsuit

MedPage Today·Jun 23

New Human Neuron Networks Decode Developing Brain Rhythms

Neuroscience News·Feb 18

Single-dose psilocybin rapidly and sustainably relieves allodynia and anxiodepressive-like behaviors in mouse models of chronic pain

Nature·Oct 2

Single dose of magic mushroom psychedelic can cause anatomical brain changes, study finds

The Guardian·May 5

Levodopa-induced dyskinesia in Parkinson’s disease: an updated review of pharmacological treatments

Frontiers·Oct 6

Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs

PR Newswire·Nov 20

Dementia: Large psilocybin dose helped in isolated case study

Medical News Today·Jun 10

A Single Dose Of Psilocybin Can Lead To 'Rapid' And 'Long-Lasting' Improvements In Depression, Study Indicates

Marijuana Moment·May 25

View original report at Stanford Report ↗

Fetching the latest headlines…